A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Park, Jun Yong ^a   Heo, Jeong ^b   Lee, Tae Jin ^c   Yim, Hyung Joon ^d   Yeon, Jong Eun ^d   Lim, Young Suk ^e   Seo, Min Jeong ^f   Ahn, Sang Hoon ^a   Lee, Myung Seok ^g  

^a Yonsei University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Monitor Group   (South Korea)

^g Hallym University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; LAMIVUDINE; TELBIVUDINE;

ADULT; ARTICLE; COST CONTROL; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FIBROSIS; HEALTH ECONOMICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KOREA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MORTALITY; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; HEALTH CARE COSTS; HEPATITIS B, CHRONIC; HUMANS; MODELS, ECONOMETRIC; MODELS, STATISTICAL; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 84874915246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057900     Document Type: Article

References (38)

1. Yim HJ, Lok AS, (2006) Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43: S173-S181.
2. Choi MS, Sinn D, Kim S, Lee YS, Choi W, et al. (2012) The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study. Gut Liver 6: 241-248.
3. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, et al. (2004) Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531.
4. Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, et al. (2008) Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol 20: 320-326.
5. Lavanchy D, (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11: 97-107.
6. Drummond M, Stoddart G, Labelle R, Cushman R, (1987) Health Economics: An Introduction for Clinicians. Ann Int Med 107: 88-92.
7. Kobelt G (2002) Health Economics: an introduction to economic evaluation. London: OHE.
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (REVEAL-HBV). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
9. Iloeje UH, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686.
10. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, et al. (2007) Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 25: 963-977.
11. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, et al. (2002) Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97: 2886-2895.
12. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, et al. (2006) Treatment alternatives for hepatitis B cirrhosis: A Cost-Effectiveness Analysis. Am J Gastroenterol 101: 2076-2089.
13. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER, (2004) Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 10: 968-974.
14. Crowley SJ, Tognarini D, Desmond PV, Lees M, (2000) Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics. 17: 409-427.
15. Crowley S, Tognarini D, Desmond P, Lees M, Saal G, (2002) Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 17: 153-164.
16. Chang TT, Lai CL, Chen CJ, (2004) Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. Hepatoloty. 19: 1276-1282.
17. Chang TT, Gish RG, De Man RA, (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 354: 1001-1010.
18. Lai CL, Shouval D, Lok AS, (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 354: 1011-1120.
19. Lai CL, Gene E, Liaw YF, (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 357: 2576-2588.
20. Liaw YF, Gene E, Leung N, (2009) 2-year globe trial results; Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 136: 486-495.
21. Hsu CW, Chen YC, Liaw YF, (2009) Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. J Hepatol 50: S331-S337.
22. Gish RG, Lok AS, Chang TT, (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 133: 1437-1444.
23. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, et al. (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis. Hepatology 51: 422-430.
24. Heo J, Park JY, Lee HJ, Tak WY, Um SH, et al. (2012) A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir Ther 17: 1563-1570.
25. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, et al. (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 52: 886-893.
26. Hadziyannis SJ, Papatheodoridis GV, (2006) Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment. Semin Liver Dis 26: 130-141.
27. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 125: 1714-1722.
28. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, et al. (2009) Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy. Hepatology 49: 1503-1514.
29. Yang BM, Kim DJ, Byun KS, Kim HS, Park JW, et al. (2010) The societal burden of HBV-related disease: South Korea. Dig Dis Sci 55: 784-793.
30. But DY, Yuen MF, Fung J, Lai CL, (2010) Safety evaluation of telbivudine. Expert Opin Drug Saf 9: 821-829.
31. Fleischer RD, Lok AS, (2009) Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 51: 787-791.
32. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, et al. (2004) Global epidemiology of hepatitis B virus. J Clin Gastroenterol 38: S158-S168.
33. Chen CJ, Wang LY, Yu MW, (2000) Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 15: E3-E6.
34. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, et al. (2010) Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 25: 892-898.
35. Calcagno JI, Augustovski F, Gadano A, Souto A, Yuan Y, (2008) Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B. Acta Gastroenterol Latinoam 38: 260--273 Spanish.
36. Lui YY, Tsoi KK, Wong VW, Kao JH, Hou JL, et al. (2010) Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 15: 145-155.
37. Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, et al. (2009) Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technology Assessment 13: 1-172.
38. Bin XU, Jia-xiu L, Jin Z, Cai-qin YU, (2005) Effects of health education on improvement of compliance of patients with CHB. Nurs J Chin PIA22: 11--22 Chinese.